Skip to main content

Table 2 NNS use during the first 21 full days of treatment; data from 1050 days of observation from 50 patients.*

From: Use of nicotine substitute prescribed at hourly plus ad libitum intake or ad libitum for heavy smokers willing to quit: a randomized controlled trial

  NNS
1 dose per hour
NNS
Ad libitum
Wald Chi2 test ICC
  Mean (CI 95%) Mean (CI 95%) p-value ρ
Doses     
   Daily number of intakes 13.6 (4.7; 22.6) 11.1 (7.3; 14.8) p = 0.332 ρ = 0.606
   Daily number of correct doses (2 puffs) 12.0 (3.9; 20.2) 9.3 (5.9; 12.7) p = 0.263 ρ = 0.593
   Daily number of single puff 0.5 (-0.4; 1.5) 0.8 (0.4; 1.2) p = 0.470 ρ = 0.414
   Daily number of doses over 2 puffs 1.1 (-0.1; 2.2) 1.0 (0.5;1.4) p = 0.780 ρ = 0.331
Period of use     
   Daily intake 1st week 13.7 (3.6; 23.8) 12.9 (8.7; 17.1) p = 0.788 ρ = 0.798
   Daily intake 2nd week 14.5 (4.4;24.6) 10.5 (6.3; 14.7) p = 0.184 ρ = 0.696
   Daily intake 3rd week 12.8 (5.6; 22.2) 9.8 (5.8;13.7) p = 0.287 ρ = 0.656
Week days     
   Daily intake weekends 13.2 (4.3; 22.2) 9.7 (6.0;13.4) p = 0.189 ρ = 0.525
   Daily intake weekdays 13.8 (4.5; 23.1) 11.6 (7.7; 15.4) p = 0.419 ρ = 0.652
Use of NNS     
   Days NNS was used 22.9 (19.0; 27.3) 23.0 (18.8;27.3) p = 0.966 -
   Total nicotine (mg) 418 (294; 543) 296 (188; 405) p = 0.131 -
  1. * Results are drawn from random-effect GLS regression taking lack of independence from measurements from the same patients into consideration.
  2. Individual level data was used for this analysis. T-test was used to calculate p-value.
  3. ‡ The Intraclass Correlation Coefficient (ρ) corresponds to the percentage of variance due to individual characteristics (cluster level).